Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most devastating human malignancies, with an overall 5 year survival rate ,5% and a median survival time of 6 months. Moreover, the almost identical annual incidence and mortality rates make it the fourth leading cause of cancer-related death worldwide (1-4). The major biological hallmarks of PDAC are its early and aggressive local invasion, metastasis and resistance to chemotherapy and radiotherapy. These traits probably contribute to the observation that the vast majority of patients presenting with advanced disease cannot be cured. The molecular basis for these characteristics of pancreatic cancer is not completely understood.
MicroRNAs (miRNAs) are endogenous non-coding RNAs consisting of [19] [20] [21] [22] [23] [24] nucleotides that play important roles in the negative regulation of gene expression by base pairing to complementary sites in the target messenger RNA (mRNA) 3#-untranslated region (UTR), thus causing a block in the translation or the degradation of the target mRNAs (5) . Mounting evidence indicates that miRNAs are aberrantly expressed in different types of tumors and play key roles in tumorigenesis (6) (7) (8) . Recently, a number of miRNAs called oncomirs that appear to function as oncogenes or tumor suppressor have been identified (9) . The downregulation of a subset of miRNAs implies a tumor suppressor function. For example, as a potential growth suppressor, downregulated let-7 in human colon cancer cells can target RAS (10) . Deleted or downregulated miR-15 and miR-16 in chronic lymphocytic leukemia suppress Bcl2 (11) . MiR-143 and miR-145 have been shown to function in tumor suppression because the overexpression of both miR-143 and miR-145 in human gastric cancer cells with low endogenous expression of these miRNAs significantly inhibits cell growth (12) . The current miRNA registry database (release 13.0, March 2009) consists of 706 human miRNA genes (13) . However, most of these genes, which are aberrantly expressed in cancers, need to be functionally defined.
A comparison of the results obtained for the miRNA expression profiles of PDAC with those for normal pancreas showed that the presence of miR-216 and miR-217 and the lack of miR-133a expression were characteristic of pancreatic tissues. Twenty-six miRNAs were aberrantly expressed in PDAC, of which only miR-217 and miR-196a were found to be differentially expressed in normal pancreas, chronic pancreatitis and cancerous tissues (14) . Regarding the function of miR-217, previous work has demonstrated that it can target oncogenes or tumor suppressor genes in different cell typespecific backgrounds. For example, miR-217 can target silent information regulator 1 (SirT1), which modulates endothelial cell senescence (15) and has been shown to function as an oncogene (16) (17) (18) . In addition, miR-217 can also target the tumor suppressor gene PTEN in kidney disorders (19) . However, no specific studies have been conducted to investigate the role of miR-217 in PDAC.
In the present study, we investigated the expression and role of miR-217 in human PDAC. First, we evaluated the expression of miR-217 in PDAC tissues, paired adjacent normal pancreatic tissues and PDAC cell lines. Second, to investigate the functional roles of miR-217 in PDAC, we examined the tumor cell growth, anchorageindependent colony formation and xenografts tumor growth following upregulation or downregulation of miR-217. Finally, we determined the target gene of miR-217 using in silico prediction and the luciferase reporter assay.
Materials and methods

Cell lines and human tissue samples
The human PDAC cell lines, including PANC-1, MIAPaCa-2, AsPC-1 and BxPC-3 cells, were purchased from the American Type Culture Collection (Rockville, MD); P1, P3 and P7 were constructed in our laboratory (20) . All cells except MIAPaCa-2 were cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf serum (Gemini Bio-Products, Woodland, CA) at 37°C in a humidified atmosphere containing 5% CO 2 . MIAPaCa-2 cells were cultured in Dulbecco's Modified Eagle's Medium. Tissues were obtained from patients undergoing PDAC surgery, collected immediately, snap frozen in liquid nitrogen and stored at À80°C until RNA extraction. After approval from the institutional review board, 21 formalinfixed paraffin-embedded PDAC specimens and 21 paired adjacent normal pancreas samples were obtained from the Department of Pathology's archival files at the Peking Union Medical College Hospital, China. All patients provided written informed consent for the use of their tissues. This project was approved by the Peking Union Medical College Hospital Clinical Research Ethics Committee, China.
In situ hybridization
Locked nucleic acid probes of the complement to human mature miR-217 (5#-TACTGCATCAGGAACTGATTGGAT-3#), the scrambled negative control and the U6 positive control, which were digoxigenin-labeled at the 3# position and purchased from Exiqon (Vedbaek, Denmark). Detection of the RNAs by in situ hybridization utilizing the oligonucleotide probes was performed according to the manufacturer's instructions. Briefly, human tissues were deparaffinized, treated with proteinase K (5 min in 2 lg/ml protease K), washed in sterile diethypyrocarbonate-treated phosphate-buffered saline and subsequently Abbreviations: miRNA, microRNA; mRNA, messenger RNA; PCR, polymerase chain reaction; PDAC, pancreatic ductal adenocarcinoma; qPCR, quantitative polymerase chain reaction; RTV, relative tumor volume; UTR, untranslated region; WT, wild-type.
Ó The Author 2010. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 1726 fixed with 4% paraformaldehyde. After prehybridization, hybridization was performed at 51°C overnight, followed by a stringency wash in 2Â standard saline citrate and 50% formamide and 3 Â 30 min washes at 51°C in 2Â standard saline citrate. After blocking (2% sheep serum and 2 mg/ml bovine serum albumin in phosphate buffered saline with Tween-20) at room temperature, the probe-target complex was visualized utilizing a digoxigenin antibody conjugated to alkaline phosphatase, which acts on the chromogen nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate. The slides were then independently scored by at least two pathologists as negative (À), weak or focally positive (1þ) or strongly positive (2þ) (21) .
RNA isolation and real-time quantitative polymerase chain reaction analysis Total RNA was extracted using TRIzol reagent (Invitrogen). For the detection of KRAS mRNA, first strand complementary DNA was synthesized from 1 lg of total RNA in the presence of oligo-dT (12-18) primer (Takara, Otsu, Shiga, Japan) and MMLV reverse transcriptase according to the manufacturer's instructions (Promega Corporation, Madison, WI). Human glyceraldehyde 3-phosphate dehydrogenase RNA was amplified in parallel as an internal control. For miR-217 detection, 1 lg of total RNA was used in the reverse transcriptase reaction with the miR-217-specific hairpin reverse primer (217-RT) (22) . The primers used to amplify mature miR-217 were designed according to Chen et al. (22) . Human U6 RNA was amplified as the internal control. Real-time quantitative polymerase chain reaction (qPCR) was performed with SYBR Green PCR Master Mix using an IQ5 Real-Time PCR Detection System (Bio-Rad, Hercules, CA). All primer sequences used for KRAS mRNA and miR-217 detection are listed in supplementary Table 1 (available at Carcinogenesis Online). Polymerase chain reaction (PCRs) were performed at 95°C for 5 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. DCt was calculated by subtracting the Ct of U6 or glyceraldehyde 3-phosphate dehydrogenase mRNA from the Ct of the mRNA of interest. DDCt was then calculated by subtracting the DCt of the negative control from the DCt of the sample. The fold change in mRNA or miRNA was calculated according to the equation 2
ÀDDCt .
DNA and reporter vectors DNA vectors. To construct a vector expressing miR-217 (217-vector), we amplified a 327 bp DNA fragment carrying precursor miR-217 from PANC-1 genomic DNA using the pre-miR-217 forward and reverse PCR primers; the fragment was inserted into the pcDNA 3.1 vector between the HindIII and BamHI sites.
Reporter vectors. To construct reporter vectors, the 1700 bp KRAS 3#-UTR containing two wild-type (WT) miR-217 recognizing sites was also amplified from PANC-1 genomic DNA using the KRAS-UTR-WT forward and reverse primers, the sequence was cloned into the pRL-TK vector between the XbaI and NotI sites. This reporter vector was called KRAS-UTR-WT. A pRL-TK reporter vector containing the 1700 bp KRAS 3#-UTR with the two seed recognizing sites mutations (MUT) between the XbaI and NotI sites was constructed from KRAS-UTR-WT using PCR as follows. The KRAS-UTR-WT-forward and KRAS-UTR-MUT1-reverse primers were used to amplify the first segment A and the KRAS-UTR-MUT1-forward and KRAS-UTR-MUT2-reverse primers were used to amplify the second segment B. A and B were annealed followed by addition of the KRAS-UTR-WT-forward and KRAS-UTR-MUT2-reverse primers to amplify the annealed A þ B sequence, providing the sequence containing the 1700 bp KRAS 3#-UTR with the two seed recognizing sites mutations (MUT). The sequence was then cloned into the pRL-TK vector between the XbaI and NotI sites. This reporter vector was called KRAS-UTR-MUT. All primers used for these constructs are listed in Supplementary Table 1 (available at Carcinogenesis Online).
Overexpression and inhibition of miR-217
The cells were transfected with 40 nM pre-miR-217 or 60 nM anti-miR-217 (Ambion, Austin, TX) by the reverse transfection method using the siPORT
TM
NeoFX
TM transfection reagent (Ambion). Cells transfected with only the siPORT TM NeoFX TM transfection reagent (mock) or a scrambled sequence, either prescramble or antiscramble (Ambion), were examined in parallel as controls. Cells were then subjected to further assays or to RNA/protein extraction after 3 days. Lipofectamine 2000 (Invitrogen) was used for transfection of the 217-vector, pcDNA3.1 or reporter gene.
CCK-8 assay
The Cell Counting Kit-8 (CCK-8) (Dojindo Laboratories, Kumamoto, Japan) allows for convenient assays cell growth by utilizing a highly water-soluble tetrazolium salt. WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2Htetrazolium, monosodium salt) produces a watersoluble formazan dye upon reduction in the presence of an electron mediator. Transiently transfected cells containing pre-miR-217, prescramble, 217-vector or pcDNA 3.1 were seeded in a 96-well plates (1000 cells per well). The following day, the media were replaced with 100 ll of complete medium containing 10 ll of CCK-8 solution. The plate was incubated for 1.5 h at 37°C and the absorbances at 450 nm and 630 nm were measured using a Vmax microplated spectrophotometer (Molecular Devices, Sunnyvale, CA). This procedure was repeated every day for at least 5 days for the pre-miR-217 transfection. For the 217-vector transfection, only the results from the first and fifth day were analyzed. The relative cell number is represented by the optical density (450-630 nm).
Anchorage-independent colony formation assay Colony formation was evaluated using a soft agar colony formation assay. A total of 1.5 ml of RPMI 1640 medium containing 10% fetal bovine serum and 0.5% agar was plated on the bottom of six-well plates. The plates were stored at 4°C to allow the agar to solidify. The cells were first seeded in six-well plates for 24 h and then transfected with pre-miR-217 or anti-miR-217 for 24 h. Subsequently, the cells were trypsinized. A number of cells per well were mixed with RPMI 1640 medium containing 10% fetal bovine serum and 0.35% agar and were plated on the prepared six-well plates (three wells per condition). The plates were then transferred to 37°C. After 14 days, the colonies were scored using a microscope. Colonies were also visualized by the addition of 3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide (Sigma-Aldrich, Poole, UK) at a concentration of 500 lg/ml. Colony formation for each condition was calculated in relation to the values obtained for the scramble-treated control cells.
Xenograft tumor studies in nude mice
Male BALB/c nude mice (nu/nu; 5 weeks of age) were obtained from Vitalriver (Beijing, China). Animal handling and experimental procedures were approved by the Peking Union Medical College animal experiments Ethics committee. PANC-1 cells were injected subcutaneously into the right dorsal region of the mice to generate a primary tumor. When the tumor xenograft diameter was .7 mm, the mice were randomized into three groups of six mice per treatment group. Tumors were injected twice with 217-vector, negative pcDNA 3.1 vector or in vivo-jetPEI TM (201-50G; Polyplus transfection, Illkirch, France) reagent only (mock group). A total of 100 lg of 217-vector or pcDNA 3.1 was injected per mouse. In vivo-jetPEI TM /DNA complexes were formed at an N/P ratio of 6:1. All procedures were performed according to the manufacturer's instructions. Tumor volumes and relative tumor volumes (RTVs) were calculated each week; after 5 weeks, the mice were killed and the tumors were dissected and photographed. Tumor volumes were calculated using the formula for hemi-ellipsoids: V 5 length (mm) Â width (mm) Â height (mm) Â 0.5236 (23) and the RTV was determined using RTV 5 V i /V 0 , where V i is the tumor volume measured weekly and V 0 is the initial tumor volume (24) . Finally, the tumors were fixed in 10% formalin and embedded in paraffin. Tissue sections were obtained and stained with hematoxylin and eosin.
Prediction of miRNA targets
To investigate the miR-217 target genes and their conserved sites bound by the seed region of miR-217, the RNA22 (http://cbcsrv.watson.ibm.com/rna22. html) and PicTar (http://pitar.mdc-berlin.de/) programs were used. The sequences of the predicted mature miRNAs were confirmed by reference to miRBase (release 13.0, http://microrna.sanger.ac.uk/).
Western blot analysis
Transfected cells were lysed on ice in lysis buffer (50 mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid, pH 7.5, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 10% glycerol and 1% Triton X-100) containing 1Â complete protease inhibitor (Roche Diagnostics GmbH, Mannheim, Germany). To assess protein phosphorylation, the buffer was also supplemented with 1 mM NaVO4, 10 mM NAF and 10 mM b-glycerophosphate. Lysates were heat denatured at 100°C for 10 min before separation in 12% sodium dodecyl sulfate-polyacrylamide gels and transferred to polyvinylidene difluoride membranes (Millipore UK Ltd, Winchester, UK). Membranes were blocked with 5% bovine serum albumin in Tris-buffered saline Tween-20 buffer (10 mM Tris, pH 7.6, 150 mM NaCl and 0.1% Tween-20) and probed with primary antibody in Tris-buffered saline Tween-20 þ 5% bovine serum albumin at the recommended dilutions at 4°C. Primary antibodies included KRAS (Ab-2) antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA), AKT antibody, phospho-AKT (p-AKT ser473) antibody (Cell Signaling Technology, Beverly, MA) and b-actin antibody (Santa Cruz Biotechnology Inc.). Membranes were incubated with secondary antibody (Santa Cruz Biotechnology Inc.) diluted in Tris-buffered saline Tween-20 þ 5% bovine serum albumin for 1 h at room temperature. The signal was detected with the enhanced chemiluminescence system (Amersham Pharmacia Biotech, Bucks, UK) and BioMax MR-1 radiographic film (Kodak, Xiamen, China). KRAS and p-AKT protein were normalized to b-actin and total AKT, respectively.
miR-217 targets on KRAS in PDAC
Immunohistochemistry analysis Immunhistochemistry was performed according to previously described methods (25) . Briefly, antigen retrieval was performed for 4 lm tissue sections in target retrieval solution (Dako, Glostrup, Denmark) by pressurized cooking at 121°C for 2.5 min in a high-pressure oven (Shunfa, Guangzhou, China). Peroxidase was then blocked by incubating the sections in 3% H 2 O 2 for 30 min; protein was blocked by incubation with normal goat serum for 30 min. The sections were then incubated overnight at 4°C with KRAS polyclonal antibody BA0280 (Boster, WuHang, China) diluted 1:300 in phosphate-buffered saline, followed by biotinylated secondary antibody and peroxidase. Peroxidase-conjugated streptavidin was used with the Dako Real Detection System and diaminobenzidine (Dako, Glostrup, Denmark) according to the manufacturer's instructions. Phosphatebuffered saline was substituted for the primary antibody as a negative control. The staining intensity in the cytoplasm was assessed by experienced pathologists.
Dual-luciferase activity assay
The 1700 bp KRAS 3#-UTR containing two miR-217 recognizing sites (KRAS-UTR-WT) was amplified and the PCR product was subcloned into a pRL-TK vector (Promega Corporation) immediately downstream of the Renilla luciferase gene. A pRL-TK construct containing the KRAS 3#-UTR with the two recognizing sites mutations (KRAS-UTR-MUT) was also constructed (refer to DNA and reporter vectors). Cells were cotransfected with 500 ng of the each reporter vectors with or without pre-miR-217 precursor or anti-miR-217 for 24 to 48 h. Each sample was cotransfected with 50 ng of pGL3-control plasmid expressing Firefly luciferase to monitor the transfection efficiency (Promega Corporation). The luciferase activity assay was performed 24 to 48 h after transfection using the dual-luciferase reporter assay system (Promega Corporation). The relative luciferase activity was normalized to that of Firefly luciferase.
Statistical analysis
Statistical analysis was performed using the SPSS 13.0 software. Unless otherwise indicated, the level of significance for the difference between data sets was assessed using one-way analysis of variance. Data are expressed as the means ± SD. P , 0.05 was considered statistically significant.
Results
MiR-217 is downregulated in PDAC tissue and cell lines
Using locked nucleic acid in situ hybridization, we showed that the expression of miR-217 was significantly lower in PDAC tissues than in paired adjacent normal pancreatic tissues ( Figure 1 , Table I ). In PDAC tissues, miR-217 was predominantly expressed in the nuclei of the ductal epithelia cells. Weak miR-217 expression was observed in five cases (5/21, 23.8%) ( Figure 1G and H) . No strong miR-217 staining was observed in cancer cells. In the adjacent normal pancreatic tissues, miR-217 was mainly expressed in acinar cells with variable expression levels. Weak and strong miR-217 expression levels were observed in 16 cases (16/21, 76.2%) ( Figure 1C and D) .
The expression of miR-217 was further assessed in a panel of seven human PDAC cell lines (PANC-1, MIAPaCa-2, AsPC-1, BxPC-3, P1, P3 and P7) and two normal pancreatic tissues (NC1 and NC2) by qPCR. The results showed that the expression of miR-217 was markedly lower in all seven PDAC cell lines than in the two normal pancreatic tissues (Figure 2A ).
MiR-217 impairs tumor cell growth, anchorage-independent colony formation and in vivo xenograft tumor growth
To assess the roles of miR-217 in cell growth, CCK-8 was used to examine the growth of PANC-1 and MIAPaCa-2 cells. The rationale for using these two cell lines is that both express a relatively low level of miR-217 compared with the normal pancreatic tissue (Figure 2A ). Cells that were transiently transfected with pre-miR-217 precursor ( Figure 2B ) or 217-vector (Supplementary Figure 1A is available at Carcinogenesis Online) were seeded into 96-well plates and a time course experiment was performed. Significant suppression of cell growth was observed in the pre-miR-217 and 217-vector transfection groups ( Figure 2C and E, Supplementary Figure 1B is available at Carcinogenesis Online). Compared with mock cells, the growth of pre-miR-217-transfected cells was inhibited 30.5% (PANC-1, Figure 2D ) and 24.7% (MIAPaCa-2, Figure 2F Furthermore, miR-217 affected not only cell growth but also anchorage-independent growth ( Figure 3A-D) . Transfection with the pre-miR-217 precursor markedly decreased the plating efficiency of PANC-1 cells ($65%) ( Figure 3A and B) and MIAPaCa-2 cells ($55%) ( Figure 3C and D) in soft agar. The results presented in Figure 2 and Figure 3 support the hypothesis that miR-217 affects cell growth as well as anchorage-independent growth in PDAC cells. Subsequently, we evaluated the effect of the 217-vector on the growth of established tumors formed by PANC-1 cells in a subcutaneous nu/nu mouse model. For the duration of the treatment with 217-vector for 5 weeks, tumor volumes and RTVs were calculated; the mice were then killed and the tumors dissected and photographed. Tumor growth curves revealed a significant decrease in growth rates at the third, fourth and fifth week after treatment with the 217-vector, whereas no significant differences in tumor growth rates were observed between the negative pcDNA 3.1 group and the mock group ( Figure 3E , Table II ). Together with the inhibitory effect on cell growth demonstrated in vitro, these results provide strong evidence that miR-217 plays a role in the suppression of PDAC cell growth. 
miR-217 targets on KRAS in PDAC
In silico prediction of the miR-217 target Using bioinformatic algorithms including RNA22 (26) and PicTar (27) for target gene prediction, KRAS, a key oncogene, was identified as one of the potential targets of miR-217. The predicted binding of miR-217 to the KRAS 3#-UTR is illustrated in Figure 4A . The sequence alignment of human miR-217 with different species of the KRAS 3#-UTR was found to be relatively conserved between humans and primates ( Figure 4B ), suggesting that KRAS is a potential direct target of miR-217.
MiR-217 regulates KRAS protein expression and AKT constitutive activation in PDAC cells PANC-1 and MIAPaCa-2 cells were transfected with pre-miR-217, prescramble control, 217-vector or pcDNA 3.1 and the results showed that upregulation of miR-217 led to a dramatic reduction in KRAS expression at the protein level ( Figure 4E and F, Supplementary Figure 1C is available at Carcinogenesis Online) but not at mRNA level ( Figure 4H , Supplementary Figure 1D is available at Carcinogenesis Online). Additional data obtained by pre-miR-217 concentration gradient transfection Previous reports have shown that KRAS gene activation will trigger the RAS/PI3K/AKT signaling pathway, which regulates cell survival, size and proliferation (28) (29) (30) . Mounting evidence indicates that this pathway plays an important role in PDAC (1). To detect the constitutive activation level of AKT following upregulation of miR-217, we assessed p-AKT expression in PANC-1 cells by western blotting. Our data demonstrated that upregulation of miR-217 via pre-miR-217 could decrease both KRAS protein expression and the level of constitutive AKT activation ( Figure 4I) .
Next, we analyzed KRAS protein expression in nude mice xenograft tumor tissues from each group by immunhistochemistry. The 217-vector group demonstrated the lowest level of KRAS protein expression among the three groups ( Figure 3F ). This result indicates that miR-217 can inhibit KRAS expression in vivo.
KRAS is a direct target of miR-217
To further confirm that KRAS is a direct target of miR-217, a 1700 bp segment of the 3#-UTR of KRAS, with or without seed sequence recognizing sites mutations ( Figure 4C ), was subcloned downstream of the Renilla luciferase reporter. The constructs were then cotransfected with pre-miR-217 precursor or anti-miR-217 or with the prescramble or antiscramble controls for the luciferase activity assays. The relative luciferase activity of the WT construct of the KRAS 3#-UTR in PANC-1 cells was significantly reduced in the presence of pre-miR-217 (P , 0.05); the relative luciferase activity of the WT construct of the KRAS 3#-UTR in MIAPaCa-2 cells was significantly increased in the presence of anti-miR-217 (P , 0.05). However, this effect was not observed in either cell line carrying the MUT construct of the KRAS 3#-UTR, highlighting the direct and specific interaction of miR-217 with the KRAS 3#-UTR ( Figure 4D ).
Inhibition of miR-217 upregulates KRAS protein expression and increases anchorage-independent colony formation ability in PDAC cells Previous results have shown that miR-217 can directly inhibit the expression of KRAS protein, PDAC cell and xenograft tumor growth and anchorage-independent colony formation. To further validate whether the inhibition of miR-217 can increase KRAS levels and facilitate PDAC progression, we assessed KRAS protein expression miR-217 targets on KRAS in PDAC and the growth of MIAPaCa-2 cells by western blot and the anchorageindependent colony formation assay, respectively, after inhibiting endogenous miR-217 expression. We found that transfection with the anti-miR-217 inhibitor significantly upregulated KRAS at the protein level ( Supplementary Figure 2A and C is available at Carcinogenesis Online) but not at the mRNA level (Supplementary Figure 2B is available at Carcinogenesis Online) and markedly increased the plating efficiency of MIAPaCa-2 cells ($67%) in soft agar, when compared with the scramble control (Supplementary Figure 2D and E is available at Carcinogenesis Online). These findings further support the results of the overexpression experiment.
Relationship between the expression of miR-217 and KRAS in PDAC cell lines To further confirm the correlation between KRAS protein and miR-217 expression levels, we assessed the expression levels of miR-217 and KRAS mRNA and protein in the seven PDAC cell lines by qPCR and western bloting, respectively (Supplementary Figure 3 is available at Carcinogenesis Online). As shown in Supplementary Figure 3C (available at Carcinogenesis Online), a negative correlation between miR-217 and KRAS protein expression was observed in all PDAC cell lines (r 5 À0.821, P 5 0.023; Spearman's correlation). However, this relationship was not observed between miR-217 and KRAS mRNA expression (r 5 À0.741, P . 0.05; Spearman's correlation; Supplementary Figure 3E is available at Carcinogenesis Online).
Discussion
The frequent aberrant expression of miRNAs implies that they have a tumor suppressor or oncogene function. Under certain circumstances, one miRNA may be expressed in different cellular locations. For example, miR-21 is predominantly expressed in the cytoplasm of luminal cells in breast cancer (31) , whereas miR-21 staining is observed in the nuclei of ductal epithelial cells in pancreatitis and is predominantly expressed in the nuclei of tumor cells with some cytoplasmic stippling in pancreatic cancer (21) . This information prompted us to examine the expression, cellular location and roles of miR-217 in PDAC development.
In agreement with previous miRNA expression profiles and qPCR results (14, 32) , the present study demonstrated that miR-217 was significantly downregulated in 21 PDAC patient tissue samples and 7 PDAC cell lines. Our locked nucleic acid in situ hybridization results further showed that miR-217 was mainly expressed in the nuclei of tumor ductal epithelial cells and normal pancreatic acinar cells. There is no clear evidence demonstrating the specific function(s) of either cytoplasmic or nuclear miRNA. However, there is a evidence that small RNAs, including miRNAs, play important nuclear roles and that some miRNAs may revisit the nucleus after being exported to the cytoplasm (33) . We speculate that the cellular location of miRNAs may influence their functional significance.
Based on the association between abnormal miRNA expression and disease, two major miRNA-based therapeutic strategies are to restore the expression of reduced miRNA expression in disease and, conversely, to abrogate overexpressed miRNA (34) . In this study, we found that overexpression of miR-217 significantly reduced PDAC cell growth and anchorage-independent colony formation. Importantly, in vivo xenograft tumor growth curves revealed a significant decrease in tumor growth rates following treatment with the miR-217 expression vector. These results indicate that miR-217 can reverse the malignant behavior of PDAC cells and may have a promising future for the treatment of PDAC.
Furthermore, we showed that miR-217 is a tumor suppressor and exerts its function by specifically targeting the KRAS oncogene. Additionally, the expression of p-AKT, a downstream molecule in KRAS signaling, was affected by miR-217 overexpression. These observations further indicate that miR-217 affects the KRAS signaling pathway.
KRAS is a crucial molecule in the development and progression of pancreatic cancer (35) . Mutation of the KRAS oncogene is the most frequent genetic alteration associated with pancreatic cancer as it has been identified in up to 90% of all PDAC cases (36) . Activating mutations of RAS-family oncogenes produce a significant array of cellular effects, including induction of proliferation, survival and invasion through the stimulation of several downstream effector pathways (37) , such as the PI3K/AKT pathway, the RAF/ERK pathway, nuclear factor-kappaB, among others (1, 38) .
Although mutation is one cause of RAS activation, the expression level and activity of the RAS oncogene can be regulated at different stages, e.g. gene transcriptional activity, posttranslational cellular localization, etc (39) . Recently, miRNAs were shown to be involved in the posttranscriptional regulation of RAS. For example, let-7 miRNA can target RAS, which suppresses the development of different cancers (10, 40, 41) . In the present study, an important molecular association between miR-217 and KRAS was demonstrated. First, KRAS protein expression in PANC-1, MIAPaCa-2 cells and in PANC-1 nude mouse xenograft tumors was significantly downregulated following upregulation of miR-217 via pre-miR-217 precursor and 217-vector, respectively, whereas the anti-miR-217 inhibitor upregulated KRAS protein expression in MIAPaCa-2 cells. Second, loss-of-function evaluation of KRAS through the upregulation of miR-217 expression suppressed tumor cell growth, anchorageindependent colony formation and in vivo xenograft tumor growth. Concurrently, gain-of-function analysis of KRAS via the downregulation of miR-217 expression facilitated anchorage-independent colony formation. Third, the negative correlation between miR-217 and KRAS protein expression in the PDAC cell lines further indicated that downregulation of miR-217, which results in upregulation of KRAS, is a potentially important feature in PDAC development. Fourth, the downregulation of KRAS expression by miR-217 inhibited the constitutive phosphorylation of AKT, a downstream molecule in KRAS signaling. Finally, our dual-luciferase reporter gene results also provided evidence that KRAS is a direct target of miR-217. Taken together, the present findings demonstrate that miR-217 can regulate KRAS expression and function as a tumor suppressor in PDAC development.
In summary, this study confirms that miR-217 is frequently downregulated in PDAC and is a potential tumor-suppressing miRNA in PDAC development. The regulation of KRAS and KRAS signaling by miR-217 might play a role in the regulation of malignant PDAC behavior. Therefore, miR-217 may serve as a useful therapeutic agent for miRNA-based PDAC therapy.
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Supplemental Figures 1-3 and Table 1 can be found at http://carcin .oxfordjournals.org/. 
